AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1. (Currently amended) A method of enhancement of an immune response level and an immunomodulating activity comprising intraperitoneally or subcutaneously administering to a subject an effective amount of an adjuvant composition with synergistic effect of low toxicity comprising

immunostimulating complex (ISCOM) particles comprising fraction A of Quil A, and

~~together with~~ at least one other adjuvant,

wherein the ISCOM particles comprising fraction A of Quil A are less toxic on VERO cells than are QH703 ISCOM matrix particles, and

the at least one other adjuvant is in free form or integrated into ~~another separate~~ ISCOM particles other than the ISCOM particles ~~in which fraction A of Quil A is integrated~~ comprising fraction A of Quil A.

Claim 2. (Currently amended) The method according to claim 1 wherein said at least one other adjuvant is chosen from the group consisting of: saponins, naturally occurring saponin molecules derived from crude saponin extract of Quillaja saponaria Molina, synthetic saponin molecules derived from crude saponin extract of Quillaja saponaria Molina, semisynthetic saponin molecules derived from crude saponin extract of Quillaja saponaria ~~Molin~~ Molina, saponin fractions from Quil A, saponin fractions from cell wall skeleton, blockpolymers, hydrophilic block copolymers, CRL-1005, Threhalose di mucolate (TDM), lipopeptides, LPS

~~derivatives,~~ and LPS-derivatives, Lipid A from a bacterial species and derivatives thereof, monophosphoryl lipid A, CpG variants, CpGODN variants, endogenous human animal immunomodulators, GM-CSF[[.]], IL-2, native adjuvant active bacterial toxins, modified adjuvant active bacterial toxins, cholera toxin CT, CT subcomponent CTB, CT subcomponent CTA1, thermolabile toxin (LT) of E. coli, Bordetella pertussis (BP) toxin, and a filamentus heamagglutenin of BP.

Claim 3. (Previously presented) The method according to claim 2 wherein the saponin fraction from Quil A is fraction C of Quil A or fraction B of Quil A.

Claim 4. (Currently amended) The method according to claim 1, wherein said at least one other adjuvant is integrated into ~~one~~ ISCOM particles other than the ISCOM particles comprising fraction A of Quil A.

Claim 5. (Currently amended) The method according to claim 1, wherein ~~said fraction A of Quil A is integrated into ISCOM particles and~~

said at least one other adjuvant is integrated into ISCOM particles other than the ISCOM particles ~~in which fraction A of Quil A is integrated~~ comprising fraction A of Quil A and is not integrated into the ISCOM particles comprising fraction A of Quil A.

Claim 6. (Cancelled).

Claim 7. (Currently amended) The method according to claim [[4]] 1, wherein ~~said fraction A of Quil A is integrated into one ISCOM particle and~~ said at least one other adjuvant is not integrated into ISCOM ~~particle~~ particles.

Claim 8. (Previously presented) The method according to claim 7, wherein said at least one other adjuvant is at least one of monophosphoryl lipid A and cholera toxin CT.

Claim 9. (Currently amended) The method according to claim [[4]] 1, wherein said ISCOM ~~particle is an~~ particles comprising fraction A of Quil A are ISCOM ~~complex~~ complexes.

Claim 10. (Currently amended) The method according to claim [[4]] 1, wherein said ISCOM ~~particle is an~~ particles comprising fraction A of Quil A are ISCOM matrix ~~complex~~ complexes.

Claim 11. (Previously presented) The method according to claim 3, wherein the composition comprises

50-99.9% of fraction A of Quil A; and

0.1-50% of the saponin fraction of Quil A based on the total weight of the composition.

Claim 12. (Previously presented) The method according to claim 11, wherein the composition comprises

75-99.9% of fraction A of Quil A; and

0.1-25% of the saponin fraction of Quil A based on the total weight of the composition.

Claim 13. (Previously presented) The method according to claim 12, wherein the composition comprises

91-99.1% of fraction A of Quil A; and

0.1-9% of the saponin fraction of Quil A based on the total weight of the composition.

Claim 14. (Previously presented) The method according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, excipient or additive.

Claim 15. (New) The method according to claim 1, wherein the immune response is an IgG response.

Claim 16. (New) The method according to claim 1, wherein the immune response is a Th1 response.

Claim 17. (New) The method according to claim 1, wherein the immune response is a Th2 response.

Claim 18. (New) The method according to claim 1, wherein the immunomodulating activity is a Th1-Th2 balance.